57 unknown, 22 recruiting, 11 completed, 10 not yet recruiting. 103 Phase 2, 25 Phase 1, 3 Phase 3.
Follow Chidamide: new trials by email Literature Review of Chidamide trials Research Report on Chidamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy of CAPCT in Patients With PTCL Chidamide, Azacitidine (AZA), Prednisone - Peripheral T-Cell Lymphoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 58 | 2026-08-01 | 2026-08-05 |
| Chidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic Syndromes Chidamide - Myelodysplastic Syndromes | Phase 2 | Not yet recruiting | Zhongshan Hospital (Xiamen), Fudan University | 15 | 2026-07-01 | 2026-06-01 |
| Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission Chidamide - Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Rong Tao | 69 | 2026-06-16 | 2026-06-18 |
| Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma Lisaftoclax, Chidamide, rituximab - Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 51 | 2026-05-30 | 2026-05-22 |
| Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL Chidamide, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Ou Bai, MD/PHD | 50 | 2026-04-30 | 2026-03-25 |
| Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL Polatuzumab Vedotin, Rituximab (R), Chidamide - Double Expressor DLBCL | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 68 | 2026-04-01 | 2026-02-17 |
| Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. Chidamide, Toripalimab, Anlotinib - Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 52 | 2026-03-31 | 2026-03-20 |
| Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma Chidamide, Sintilimab, Bevacizumab - Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) | Phase 2 | Recruiting | Sun Yat-sen University | 34 | 2026-03-27 | 2026-04-08 |
| PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL PD-1 antibody, radiotherapy, Chidamide - Natural Killer/T-cell Lymphoma | Phase 2 | Recruiting | Ruijin Hospital | 47 | 2026-03-01 | 2026-03-20 |
| CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL Chidamide, Rituximab, Polatuzumab Vedotin - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 58 | 2026-02-03 | 2026-07-29 |
| EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas Zeprumetostat, Golidocitinib, Chidamide - Mature T-cell and NK-cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 60 | 2026-01-01 | 2026-01-14 |
| Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor Dalpiciclib, Chidamide, Enitinostat - HR+/HER2- Advanced Breast Cancer | Phase 2 | Not yet recruiting | Beijing 302 Hospital | 155 | 2025-10-01 | 2025-08-13 |
| Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma Linperlisib, Chidamide - Peripheral T Cells Lymphoma (PTCL) | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 54 | 2025-09-15 | 2025-08-24 |
| Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML Chidamide - Allogeneic Hematopoietic Cell Transplantation (HCT), AML (Acute Myeloid Leukemia) | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 134 | 2025-09-01 | 2025-12-26 |
| Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients VEN (Venetoclax), Azacitidine (AZA), Chidamide - Adult T-cell Leukemia/Lymphoma | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 27 | 2025-09-01 | 2026-10-16 |
| Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma Golidocitinib, Mitoxantrone Hydrochloride Liposome, Chidamide - Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Sun Yat-sen University | 101 | 2025-08-27 | 2025-12-31 |
| Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma golidocitinib, Chidamide - Cutaneous T-cell Lymphoma (CTCL) | Phase 1 / Phase 2 | Recruiting | Peking Union Medical College Hospital | 65 | 2025-08-26 | 2026-08-12 |
| QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer QL1706, Chidamide, Gemcitabine - Metastatic Pancreatic Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 33 | 2025-03-07 | 2026-01-26 |
| Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL Glofitamab, Chidamide - Diffuse Large B-Cell Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Refractory | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 22 | 2025-02-27 | 2026-08-03 |
| Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy Drug therapy - DLBCL, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | First Affiliated Hospital of Ningbo University | 50 | 2025-01-15 | 2025-03-18 |
Showing 20 of 103. Sign in to see all of them.
Lymphoma, T-Cell, Peripheral (12) · Lymphoma, Large B-Cell, Diffuse (11) · Recurrence (8) · Leukemia, Myeloid, Acute (6) · Lymphoma, Non-Hodgkin (6) · Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Immunoblastic Lymphadenopathy (4) · Leukemia (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Neoplasms, Experimental (3) · Carcinoma, Neuroendocrine (2) · Hodgkin Disease (2) · Leukemia, T-Cell (2) · Lymphoma (2)
Sun Yat-sen University (16) · Peking Union Medical College Hospital (6) · Ruijin Hospital (6) · Chinese PLA General Hospital (5) · Sichuan University (5) · The First Affiliated Hospital of Soochow University (5) · Chipscreen Biosciences, Ltd. (4) · Institute of Hematology & Blood Diseases Hospital, China (4) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Nanfang Hospital, Southern Medical University (3) · Peking University (3) · The First Affiliated Hospital with Nanjing Medical University (3) · Tianjin Medical University Cancer Institute and Hospital (3) · Chinese Academy of Medical Sciences (2) · Fudan University (2)
China (90) · Taiwan (3)
Chia-Nan Chen, Ph.D. (2) · Chunmei Bai, M.D. (2) · Susen Wang, MD (2) · Ting Liu, MD (2) · Binghe Xu (1) · Biyun Wang (1) · Caicun Zhou (1) · Caigang Liu, doctoral (1) · Daobin Zhou, M.D (1) · Dehui Zou, Dr. (1) · Dongmei Ji, doctor (1) · Feng Wang, MD, PhD (1) · Haitao Wang, Ph.D (1) · Hongsheng Zhou, MD, PhD (1) · Huilai Zhang (1)
PMID 18213528, PMID 18824292, PMID 1950172, PMID 20686505, PMID 21390126, PMID 21796119, PMID 22080169, PMID 22339555, PMID 22362161, PMID 22851565, PMID 24721323, PMID 25652253, PMID 25712263, PMID 27717585, PMID 30209556, PMID 31724191, PMID 32299513, PMID 33097085, PMID 34398971, PMID 35170082, PMID 35659479, PMID 37488286, PMID 38438735, PMID 38805037, PMID 39093981, PMID 39468701, PMID 40802906, PMID 41080407, PMID 41366419, PMID 41428995